Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines
Nov
8
2018
On demand

Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines

Thursday 07:00 PST / 10:00 EST / 15:00 GMT / 16:00 CET
Sponsor
Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines

Current production methods for viral vectors tend to use adherently growing cells and transient transfection, a manual process which allows only for scale-out and not for scale-up. Upscaling GMP production of viral vectors is currently one of the big technical challenges in gene therapy manufacture. CEVEC has developed the fully scalable CAP-GT platform, based on serum-free suspension cells which can efficiently produce lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) vectors at industrial scale.

Watch this On Demand webinar with Dr Nicole Faust, CEO & CSO of CEVEC Pharmaceuticals GmbH, to gain insight on the newly developed AAV packaging system, allowing the helper virus-free stable production of AAV vectors without the need of a transient transfection step. Dr Faust will discuss:

  • The challenges of AAV vector production – such as how using standard suspension cells for scale-up can result in relatively poor efficiency & reproducibility during transient transfection;
  • Problems with current manufacturing methods, in particular when addressing more common diseases with gene therapy approaches, for example how with Alzheimer’s, Parkinson’s etc, bottlenecks in manufacturing arise during late stage clinical trials and when entering the market;
  • How the CAP-GT platform can address scale-up challenges;
  • Current AAV production platforms – different manufacturing systems have been developed for the large-scale production of AAV vectors for research, development, clinical evaluation and routine use for the treatment of rare diseases;
  • Data on novel stable, helper virus-free CAP-GT platform – how growing cells in serum-free suspension culture at high densities can provide a fully scalable vector production platform.

[#speakersPlaceHolder]

Nicole Faust
Nicole Faust
General Manager Cell Line Development at Cevec Pharmaceuticals, now part of Cytiva
Dr. Nicole Faust has extensive management experience in the biotechnology sector. Over the last 18 years she has held scientific management positions with Artemis/Taconic Biosciences, amaxa, Lonza, and CEVEC, engaging in the fields of pharmaceutical models, gene transfer, protein production, and gene therapy. She received her Ph.D. from University of Freiburg and an MBA degree from Educatis University, Switzerland.

SPEAKERS

Nicole Faust
Nicole Faust
General Manager Cell Line Development at Cevec Pharmaceuticals, now part of Cytiva

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual
27 June
in 69
Days
Register
Pure and simple: understanding LNP analytics for better mRNA-based drugs

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe
29 May
in 40
Days
Register
Empowering patient care: in-process and quality control solutions for cellular therapies

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz
23 May
in 34
Days
Register
T cells from beginning to end: optimizing leukopak and drug product cryopreservation

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity
22 May
in 33
Days
Register
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes
21 May
in 32
Days
Register